Company profile for Mapi Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a late clinical stage pharmaceutical company, engaged in the development of improved extended-release versions of existing commercially successful products, which we refer to as life cycle management, or LCM products, that target large markets, as well as high-barrier to entry and high-added value generic drugs. Our core capabilities are in long acting depot injectable drugs that are complex formulations in sterile prod...
We are a late clinical stage pharmaceutical company, engaged in the development of improved extended-release versions of existing commercially successful products, which we refer to as life cycle management, or LCM products, that target large markets, as well as high-barrier to entry and high-added value generic drugs. Our core capabilities are in long acting depot injectable drugs that are complex formulations in sterile production. We are fully integrated in our activities and are built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs. Mapi is headquartered in Israel.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Weizmann Science Park 16 Einstein St. P.O. Box 4113 Ness Ziona, Israel 74140
Telephone
Telephone
+972-73-7121213
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3197080/0/en/Mapi-Pharma-is-Seeking-New-Partnerships-for-Long-Acting-Depot-Drugs-of-Peptides-for-Self-Administration.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/09/17/3151767/0/en/Mapi-Pharma-Announces-First-Patient-Recruited-in-Phase-I-II-Study-of-Cariprazine-Depot-Once-Monthly-Injection.html

GLOBENEWSWIRE
17 Sep 2025

https://www.biospace.com/article/fda-rejects-viatris-mapi-s-long-acting-multiple-sclerosis-injection/

BIOSPACE
12 Mar 2024

https://www.prnewswire.com/news-releases/viatris-and-mapi-pharma-announce-fda-acceptance-of-new-drug-application-filing-for-ga-depot-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-301894145.html

PR NEWSWIRE
07 Aug 2023

https://www.prnewswire.com/news-releases/viatris-and-mapi-pharma-to-highlight-latest-results-of-multiple-sclerosis-research-at-american-academy-of-neurology-75th-annual-meeting-301804983.html

PR NEWSWIRE
24 Apr 2023

https://www.globenewswire.com/news-release/2022/10/12/2533105/37187/en/Mapi-Pharma-to-Host-a-Key-Opinion-Leader-Webinar-on-Glatiramer-Acetate-Depot.html

GLOBENEWSWIRE
12 Oct 2022

Services

Upload your portfolio for free, ask us

API & Drug Product Development

Click here to discover the service providers for API & Drug Product Development

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty